Mainstream

Neogenomics outlines revised 2025 outlook with 9% 10% revenue growth target amid pharma headwinds and pantracer launch

NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch

NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch

Post ContentneoRead More

You might also be interested in reading US Inflation Remains Higher Than Expected, Raising Concerns Among Investors.

July 29, 2025
In Mainstream